Literature DB >> 15217328

Desensitization of G protein-coupled receptors and neuronal functions.

Raul R Gainetdinov1, Richard T Premont, Laura M Bohn, Robert J Lefkowitz, Marc G Caron.   

Abstract

G protein-coupled receptors (GPCRs) have proven to be the most highly favorable class of drug targets in modern pharmacology. Over 90% of nonsensory GPCRs are expressed in the brain, where they play important roles in numerous neuronal functions. GPCRs can be desensitized following activation by agonists by becoming phosphorylated by members of the family of G protein-coupled receptor kinases (GRKs). Phosphorylated receptors are then bound by arrestins, which prevent further stimulation of G proteins and downstream signaling pathways. Discussed in this review are recent progress in understanding basics of GPCR desensitization, novel functional roles, patterns of brain expression, and receptor specificity of GRKs and beta arrestins in major brain functions. In particular, screening of genetically modified mice lacking individual GRKs or beta arrestins for alterations in behavioral and biochemical responses to cocaine and morphine has revealed a functional specificity in dopamine and mu-opioid receptor regulation of locomotion and analgesia. An important and specific role of GRKs and beta arrestins in regulating physiological responsiveness to psychostimulants and morphine suggests potential involvement of these molecules in certain brain disorders, such as addiction, Parkinson's disease, mood disorders, and schizophrenia. Furthermore, the utility of a pharmacological strategy aimed at targeting this GPCR desensitization machinery to regulate brain functions can be envisaged.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217328     DOI: 10.1146/annurev.neuro.27.070203.144206

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  353 in total

Review 1.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 2.  Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop.

Authors:  Kohji Fukunaga; Norifumi Shioda
Journal:  Mol Neurobiol       Date:  2011-12-20       Impact factor: 5.590

3.  Large putative PEST-like sequence motif at the carboxyl tail of human calcium receptor directs lysosomal degradation and regulates cell surface receptor level.

Authors:  Xiaolei Zhuang; John K Northup; Kausik Ray
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

Review 4.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 5.  Alan [corrected] N. Epstein award: Intracellular signaling and ingestive behaviors.

Authors:  Derek Daniels
Journal:  Physiol Behav       Date:  2010-03-25

Review 6.  Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection.

Authors:  Gregor Zündorf; Georg Reiser
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

Review 7.  G protein modulation of CaV2 voltage-gated calcium channels.

Authors:  Kevin P M Currie
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

8.  Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Authors:  Laura C Sullivan; Teresa S Chavera; Raehannah J Jamshidi; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-22       Impact factor: 4.030

9.  Sorting nexin 27 regulation of G protein-gated inwardly rectifying K⁺ channels attenuates in vivo cocaine response.

Authors:  Michaelanne B Munoz; Paul A Slesinger
Journal:  Neuron       Date:  2014-05-07       Impact factor: 17.173

10.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.